No Data
Haisco Pharmaceutical Group (002653.SZ): has obtained the "Notice of Drug Clinical Trial Approval" for the innovative drug HSK46575 tablets.
On December 4th, Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The tablet is named HSK46575 Tablet and is intended for the treatment of prostate cancer. HSK46575 Tablet is a self-developed oral, potent, and highly selective small molecule inhibitor designed for the treatment of prostate cancer. Preclinical research results indicate that this product has a clear target, precise efficacy, and good safety profile, making it a highly promising small molecule drug with significant potential for development. The benefits/risks of clinical application.
Will 2025 no longer be the era of the magnificent 7? Bank of America is bullish on this type of stocks...
①The chief strategist of Bank of America predicts that cyclical stocks (such as csi commodity equity index, construction, and infrastructure) will rise strongly, as investors will flow into the "old economy" sector; ②She believes that the USA economy is ready for a new spending cycle, and expects the s&p 500 index to rise to 6666 points next year.
Cisco Systems, Inc. (CSCO) Management Presents at 2024 UBS Global Technology and AI Conference (Transcript)
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
The Top 20 Technology Stocks Ranked by Quant
Cisco Systems To Present At 2024 UBS Global Technology And AI Conference; Webcast At 12:55 PM ET
